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Protocol
AbstrACt
background Achilles tendon injuries give rise to 
substantial long-lasting morbidity and pose considerable 
challenges for clinicians and patients during the lengthy 
healing period. Current treatment strategies struggle 
to curb the burden of this injury on health systems and 
society due to lengthy rehabilitation, work absence and 
reinjury risk. Platelet-rich plasma (PRP) is an autologous 
preparation that has been shown to improve the 
mechanobiological properties of tendons in laboratory and 
animal studies. The use of PRP in musculoskeletal injuries 
is on the increase despite the lack of adequately powered 
clinical studies.
Methods and design This is a multicentre randomised 
controlled trial to evaluate the efficacy and mechanism of 
PRP in patients with acute Achilles tendon rupture (ATR). 
All adults with acute ATR presenting within 12 days of the 
injury who are to be treated non-operatively are eligible. A 
total of 230 consenting patients will be randomly allocated 
via a remote web-based service to receive PRP injection or 
placebo injection to the site of the injury. All participants will 
be blinded to the intervention and will receive standardised 
rehabilitation to reduce efficacy interference. Participants 
will be followed up with blinded assessments of muscle–
tendon function, quality of life, pain and overall patient’s 
functional goals at 4, 7, 13, 24 weeks and 24 months post-
treatment. The primary outcome is the heel-rise endurance 
test (HRET), which will be supervised by a blinded assessor 
at 24 weeks. A subgroup of 16 participants in one centre 
will have needle biopsy under ultrasound guidance at 
6 weeks. Blood and PRP will be analysed for cell count, 
platelet activation and growth factor concentrations.
Ethics and dissemination The protocol has been 
approved by the Oxfordshire Research Ethics Committee 
(Oxfordshire Research Ethics Committee A, reference no 
14/SC/1333). The trial will be reported in accordance with 
the CONSORT statement and published in peer-reviewed 
scientific journals.
trial registration number ISRCTN: 54992179, assigned 
12 January 2015.  ClinicalTrials. gov: NCT02302664, 
received 18 November 2014. UK Clinical Research 
Network Study Portfolio Database: ID 17850.
IntroduCtIon
Achilles tendon rupture (ATR) incidence is 
21/100 000/year.1 ATR accounts for 20% of 
all tendon ruptures and leads to major health-
care and societal costs. The current treat-
ment strategies are either augmentation with 
surgical suture or immobilisation in a cast or 
boot. The mechanical and biological proper-
ties of healed tendons appear never to match 
those of the original intact tendons, leading 
to high risk of further injury (5%–15%) or 
reduced function.2–4 Moreover, a Cochrane 
review reported mean ATR rehabilitation and 
work absence of 63–108 days.5 
Platelet-rich plasma (PRP) is a derivative of 
the patient’s own blood (autologous blood) 
that contains a supraphysiological concentra-
tion of platelets. Platelets contribute to injury 
healing by releasing an ordered sequence 
of growth factors, cytokines and an array of 
bioactive proteins in soluble and membrane-
bound forms over the lifespan of the plate-
lets.6 7 These include transforming growth 
factor (TGF-β1 and TGF-β2), platelet-de-
rived growth factor (PDGF-AA, PDGF-AB 
and PDGF-BB), vascular endothelial growth 
factor (VEGF-A and VEGF-C), insulin-like 
growth factor 1 (IGF-1) and epidermal growth 
factor.7 8 These factors recruit a range of cell 
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types, including the injured tendon’s tenocytes, leucocytes 
and local stem cells, and promote the healing pathway. 
PRP enhances angiogenesis, stem cell homing, local cell 
migration, proliferation and differentiation coupled with 
the deposition of proteins such as collagen which plays a 
key role in enabling the restoration of normal tissue struc-
ture and functional proliferation of human tenocytes.8 9
PRP is prepared from autologous blood using gravita-
tional platelet sequestration centrifugation, cell separa-
tors or selective filtration technology (plateletpheresis). 
Each preparation technique has been evidenced to result 
in significant differences in yields, concentration, purity, 
viability and activation status of the platelets.10 Each of 
these variables will not only influence the eventual concen-
trations of the bioactive proteins but may also affect the 
clinical efficacy of each PRP preparation.11 We selected a 
centrifugation technique with highly standardised prepa-
ration protocol that offers consistently viable and active 
PRP with a high concentration of platelets and leucocytes 
(leucocyte-rich PRP (L-PRP)).12
To date, there is only one randomised controlled trial 
(RCT) that has assessed PRP in ATR, and in this study of 
30 participants treated surgically, no effect of platelets on 
radioisometrical tendon contraction was seen13; the use 
of PRP as an adjunct to open surgical repair may have 
obscured any effect of PRP on healing. In a case–control 
study of 12 athletes treated with PRP, positive effects at 32 
months after treatment were demonstrated.14 Less tendon 
thickening and higher concentrations of TGF-β and other 
growth factors were seen in the intervention patients, 
who also regained range of motion faster and returned to 
gentle running earlier.14 Systematic reviews15 16 concluded 
that there are encouraging signs that PRP could be devel-
oped as an effective tendon therapy, with potentially 
faster recovery and, possibly, a reduction in injury, with no 
adverse reactions described.16 Both reviews emphasised 
the need for an adequately powered RCT to establish PRP 
efficacy with disease-specific outcome measures.
We describe the first multicentre RCT to evaluate the 
efficacy and mechanism of PRP in patients with acute ATR, 
where adequate power and robust, validated, objective 
and participant-reported outcome measures will ensure 
successful efficacy evaluation. Our aim is to investigate 
if the efficacy signal for PRP identified in basic science 
translates to improved mechanical muscle–tendon unit 
recovery in patients with acute ATR. The primary objec-
tive is to evaluate the clinical efficacy of PRP in acute ATR 
in terms of mechanical muscle–tendon function. The 
secondary objectives are to evaluate the clinical efficacy 
in terms of participant reported functional recovery, pain 
and quality of life; determine the key components of PRP 
that contribute to its mechanism of action; further under-
stand in an immunohistochemical substudy the mecha-
nisms of PRP which may account for its clinical efficacy 
and identify the histological pathways that PRP may alter 
to exert its effects.
MEthods
study design
A prospective multicentre, participant and outcome 
assessor blinded randomised placebo-controlled supe-
riority trial, which aims to evaluate the clinical efficacy 
of PRP in acute ATR in terms of recovery of the tendon 
function. Two hundred and thirty participants will be 
randomised to receive a PRP or placebo injection after 
attending the orthopaedic or trauma outpatient clinics 
within 12 days of the injury in at least 18 National Health 
Service (NHS) hospitals. Two substudies are embedded 
in the main study to evaluate the mechanism of action 
and PRP components. The substudies are: (1) immu-
nohistochemistry analysis of ultrasound-guided needle 
Table 1 Participant’s inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
 ►Willing and able to give informed consent 
for participation
 ► Age ≥18 years
 ► Diagnosed with an acute complete Achilles 
tendon rupture
 ► Presenting within and receiving study 
treatment within 12 days postinjury
 ► Patients in whom the decision has been 
made for non-operative treatment
 ► Ambulatory prior to injury without the use 
of walking aids or assistance of another 
person
 ► Able and willing to comply with all study 
requirements
 ► Able to attend the 24-week follow-up at a 
PATH-2 study hospital site
 ► Achilles tendon injuries at the insertion to the calcaneum or at the 
musculotendinous junction
 ► Previous major tendon or ankle injury or deformity to either lower leg
 ► History of diabetes mellitus
 ► Known platelet abnormality or haematological disorder
 ► Current use of systemic cortisone or a treatment dose of an anticoagulant
 ► Evidence of lower limb gangrene/ulcers or peripheral vascular disease
 ► History of hepatic or renal impairment or dialysis
 ► Pregnant or breast feeding
 ► Currently receiving or has received radiation or chemotherapy within the last 
3 months
 ► Has inadequate venous access for drawing blood
 ► Has any other significant disease or disorder which, in the opinion of 
the recruiting clinician, may either put the participant at risk because of 
participation in the study, influence the result of the study or influence the 
patient’s ability to participate in the study
PATH-2, Platelet Rich Plasma in Achilles Tendon Healing 2.
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biopsies from 16 participants at one centre (Oxford) 
and (2) whole blood and PRP component analysis in 
all participants. A whole blood sample will be obtained 
from each participant prior to intervention. In the PRP 
group, a small volume of PRP will be used to analyse the 
biological components. Blood and PRP analysis will be 
carried out at a central specialised laboratory (Institute 
of Inflammation and Ageing Laboratory at the University 
of Birmingham).
Through immunohistochemical, PRP and blood anal-
ysis, the potential mechanism of action will be studied to 
determine the key components of PRP that contribute to 
its effect. Linking the outcomes and the embedded labo-
ratory analysis will allow us to evaluate the effect of vari-
ability of this biological product on the clinical outcome.
study participants
All patients with acute ATR attending outpatient trauma 
or orthopaedic clinic within 12 days of sustaining the 
injury are eligible for the trial if they meet all of the inclu-
sion criteria and none of the exclusion criteria (table 1). 
At least 18 UK NHS hospitals will participate to recruit 
the required 230 patients. A list of participating sites to 
date can be found on the Platelet Rich Plasma in Achilles 
Tendon Healing 2 (PATH-2) website17 and in an online 
supplementary table .
Centre recruitment
A minimum of 18 NHS hospital orthopaedic trauma/
outpatient clinics will recruit 230 participants for the 
trial. Each site will identify a surgeon to act as PATH-2 
Principal Investigator (PI). The PI oversees the study 
protocol implementation at each site, uses links with local 
physiotherapy departments to facilitate the standardised 
rehabilitation and arranges for a blinded physiotherapist 
who will be the assessor for the heel-rise endurance test 
(HRET) primary outcome measurement. The trial team 
will assess each centre to ensure the site is equipped with 
appropriate resources to deliver the project and meet 
recruitment targets.
Participant recruitment
Participants will be identified in the outpatient trauma 
or orthopaedic clinic. The treating surgeon or extended 
scope physiotherapist will confirm the diagnosis, appro-
priateness for conservative treatment and study eligibility. 
A member of the research team at the site will carry out 
the informed consent process, baseline data collection 
and randomisation.
Informed consent
The timeframe between attending clinic and receiving 
the intervention is relatively short. To help raise awareness 
of the study during the clinic wait, sites will be provided 
with written study participant information (including 
posters) to display in clinic where potential participants 
are waiting to be seen by the surgeon or extended scope 
physiotherapist.
The attending surgeon or extended scope physiother-
apist will meet with the participant for the clinical exam-
ination and decide if the management will be operative 
or non-operative. If non-operative, participants will be 
informed of the study and given a patient information 
sheet (PIS). The participant will be allowed as much 
time as practically possible in this type of acute injury to 
consider the information and will have the opportunity to 
ask questions of the attending clinician and a member of 
the research team.
The person who obtains the consent must be a regis-
tered health or medical practitioner who is Good Clinical 
Practice (GCP) trained and has been authorised to do so 
by the PI. In most sites, this is a research nurse or physio-
therapist or surgeon who will be a part of the local NHS 
Trust or the local National Institute of Health Research 
(NIHR) clinical research network. The participant must 
sign and date the informed consent form before any 
study-specific procedures are performed. Participants will 
also be asked to consent to use of their data, biological 
specimens and videos of their HRET test (view is of leg 
only). A copy of the signed informed consent form will 
be given to the participants, and one copy will be sent to 
the study coordinating team. The original signed consent 
form will be retained in the medical notes and a copy 
held in the Investigator Site File.
baseline assessment
Baseline data are collected immediately following confir-
mation of eligibility and consent. Background and 
Table 2 Primary outcome measures
Primary outcome measure: HRET
Measurement Work (J) of each limb in heel-rise test
Analysis variable LSI
Description
LSI = Injured Limb measurementUninjured Limb measurement x 100
Method of aggregation Mean±SD
Time point 24 weeks postintervention
HRET other variables Number of heel raises performed by each limb
Maximum displacement during the HRET for each limb (cm)
HRET, heel-rise endurance test; LSI, Limb Symmetry Index.
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demographic information is collected including: general 
health, current medication, allergies, smoking, alcohol 
use, age, sex, employment status, type of employment, 
activities of daily living, sport and recreational activities 
prior to injury, the activity that led to the injury, previous 
history, height and weight. The Achilles Tendon Rupture 
Score (ATRS), a validated and responsive participant-re-
ported outcome measure (PROM), is collected.18 19 
In addition, PROMs: Patient-Specific Functional Scale 
(PSFS),20 21 Visual Analogue Scale (VAS) pain indi-
cator22 and the acute version 12-Item Short Form Health 
Survey (SF-12) assessment.23 The latter is collected as 
recalled before injury and also on the day of treatment 
(table 2). The recall of SF-12 health status and physical 
ability in the 4 weeks prior to the injury is a valid method 
considering the acute occurrence of the injury and the 
short period to recruitment (up to 12 days).
randomisation
Participants will be randomly allocated (1:1) to the two 
groups (treatment and placebo groups) via a central 
computer-based allocation randomisation system 
provided by the Oxford Clinical Trials Research Unit 
(OCTRU). The randomisation will use minimisation, 
stratified by study site and age group (<55 and ≥55 years) 
and with a probabilistic element of 0.8 to reduce predict-
ability for this multicentre trial while retaining balance 
within centre and ensure overall balance at the end of the 
study.24 Participants will remain blind to their allocated 
treatment throughout the study.
Interventions
The two trial groups are:
 ► PRP injection (treatment group): After local anaes-
thetic injection, PRP is injected into the tendon 
rupture gap.
 ► Imitation injection (placebo group): After local 
anaesthetic injection, a needle is introduced into 
the tendon rupture gap, held briefly and withdrawn 
without injecting and without disturbing the biolog-
ical haematoma.
Immediately after randomisation, up to 55 mL of 
venous blood is withdrawn from the participant regard-
less of the random allocation. The exact amount of blood 
and the volume of PRP injected are not stated in the 
PIS as this information has the potential to non-blinded 
participants.
PRP will be prepared from the venous blood by a 
study-specific centrifuge (MAG 200 MAGELLAN Autolo-
gous Platelet Separator, Arteriocyte Medical Systems) in 
or near the clinic (figure 1). This device has been found 
to produce around a fivefold concentration of platelets 
with 76% platelet recovery.12 This is a fully automated 
system, requiring a sterile PRP disposable kit (MDK 300/
MDK 300-1, Arteriocyte Medical Systems) and a single 
preparation step, reducing the risk of protocol deviation 
while in use.
Both interventions will be delivered by a clinician or 
extended scope physiotherapist while maintaining the 
participant’s blinding to the allocation. Both interven-
tions are delivered by the same technique. The patient is 
positioned lying face down on a treatment bed with the 
tendon exposed. The tendon gap is palpated clinically 
to identify the injection site. The area is cleaned, and 
1–2 mL local anaesthetic is used to anaesthetise the skin 
only. In PRP injection group, half of the PRP is injected 
in the tendon gap (figure 1D), and the remaining PRP 
Figure 1 Making autologous PRP in the PATH-2 study. (A) 
A whole blood sample is taken. (B) The Magellan Autologous 
Platelet Separator System is used to produce PRP. (C) The 
resulting PRP is collected in a syringe for injection into the 
Achilles tendon rupture gap. (D) The injection is delivered 
in the tendon rupture gap. PATH-2, Platelet Rich Plasma in 
Achilles Tendon Healing 2; PRP, platelet-rich plasma.
Table 3 Secondary outcome measures
Time point Outcome measures
Baseline ATRS, PSFS, SF-12 (preinjury and 
postinjury), VAS (pretreatment)
Substudy 1: blood sample (both 
groups), PRP analysis (PRP group)
2 weeks Daily record of post-treatment pain 
using daily pain diary (VAS)
6 weeks Substudy 2: tendon needle biopsy 
under ultrasound guidance analysis
(16 participants, 8 in each arm, central 
site) Immunohistochemistry analysis
4, 7 and 13 weeks ATRS, PSFS and SF-12
Recorded by telephone call or during 
outpatient visit
24 weeks ATRS, PSFS, SF-12, HRET
Conducted via assessment at 
outpatient visit
24 months ATRS, PSFS and SF-12
recorded by telephone call
ATRS, Achilles Tendon Rupture Score; HRET, heel-rise endurance 
test; PRP, platelet-rich plasma; PSFS, Patient-Specific Functional 
Scale; SF-12, 12-Item Short Form Health Survey; VAS, Visual 
Analogue Scale.
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is kept for analysis. In the imitation group, the same size 
needle is inserted into the tendon gap, held briefly and 
withdrawn without injecting anything.
As this study requires a single treatment, adherence 
to the protocol consists of the participant receiving the 
allocated treatment. This will be monitored, and every 
instance of the participant not receiving the allocated 
treatment will be investigated. Unless they request to 
withdraw, these participants will be retained in the trial, 
to avoid missing data and for follow-up. However, if a 
participant is unable to receive a PRP injection for any 
technical reasons, they will receive an imitation injection, 
and this will be recorded.
Training in delivery of the PRP injection and the imita-
tion injection will be provided by the trial team, and a step-
by-step manual is provided to each site. Video training 
materials are available to site staff via an access-controlled 
website25 but not supplied here because of the potential 
for non-blinding.
blIndIng ProCEdurE
It will not be possible to blind the research nurse, surgeon 
or extended scope physiotherapist involved in treatment 
preparation or delivery due to the nature of the interven-
tion. However, the participant and the assessor for the 
Figure 2 The patient pathway for the main study. The substudies are not shown in this diagram. NHS, National Health Service; 
PRP, platelet-rich plasma.
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primary outcome are blinded. The participant will be 
shielded from the injection preparation as this is done in 
another room or while the participant is waiting outside 
the clinic. To reduce the risk of non-blinding, participants 
in both intervention groups will wait for approximately 
17 min, the duration of a cycle for the PRP preparation, 
and not be in direct sight of the machine. If the machine 
is not out of earshot, a dummy cycle will be run on the 
machine. The participant will receive the injection while 
lying face down and visually obscured from the proce-
dure. The primary outcome assessor will not be aware of 
allocation when they perform the HRET at 24 weeks after 
treatment.
standardisation of other treatments
All participants receive standard care at the participating 
site. Standard treatment for the non-surgical population 
is usually immobilisation of the ankle in a cast, splint 
or boot during the initial clinic visit. Immediately after 
the intervention (PRP or imitation), the ankle will be 
immobilised in a cast, splint or boot. Standardisation of 
key elements of rehabilitation is required for this trial to 
reduce the risk of efficacy interference from substantial 
variation in rehabilitation. The following milestones are 
standardised:
 ► duration of initial ankle immobilisation postinterven-
tion is at least 3 weeks,
 ► position of the foot and ankle in equinus during the 
initial immobilisation,
 ► referral to physiotherapy for rehabilitation,
 ► avoidance of rigid full-time immobilisation or 
non-weight-bearing for more than 6 weeks.
Standardisation will not be required for the ankle 
splinting method or device, when weight-bearing is 
commenced or the specific exercise prescription. We 
will standardise rehabilitation by providing guidance to 
surgeons and physiotherapists in written form. Moni-
toring adherence with these guidelines will be assessed 
by asking participants questions relating to progress with 
rehabilitation during follow-up.
objectives and outcome measures
The primary objective is to evaluate the clinical efficacy 
of PRP in acute ATR in terms of muscle–tendon func-
tion. The primary outcome measure is work in Joules 
derived from the HRET, which is a validated objective 
measure of Achilles tendon–muscle unit function at 24 
weeks to evaluate efficacy.26 Preceded with a warm-up 
activity of walking for 5 min, the test is first performed 
on the uninjured limb and then on the injured side. The 
HRET involves the participant standing on one leg on 
a 10° incline box, raising the heel for maximum height 
and lowering the heel repeatedly at a rate of 30 raises 
per minute guided by a digital metronome until task 
failure. Vertical displacement data from the movements 
are obtained using a computer-controlled linear encoder 
(Encoder, MUSCLELAB; Ergotest Innovation AS, Pors-
grunn, Norway) that measures the height of each heel-
rise repetition and integrates the data into custom-made 
software (PATH-2, MUSCLELAB; Ergotest Innovation 
AS, Porsgrunn, Norway). Work (Joule) is calculated as 
the product of body mass (kilogram, measured on class 
III scales), total vertical displacement (metre) and the 
constant 9.807 converting kilopond-metres to Joules. We 
will also report the number of repetitions and maximum 
heel-rise height (centimetre). The performance of 
the injured limb for each of the three variables will be 
box serious adverse events
An adverse event is considered a serious adverse event if it 
satisfies at least one of the following criteria:
 ► Results in death
 ► Is life-threatening
 ► Requires in-patient hospitalisation or prolongation of existing 
hospitalisation
 ► Results in persistent or significant disability/incapacity
 ► Results in congenital anomaly or birth defect
 ► Another medical event judged important in the opinion of the 
investigator
Table 4 AEs not qualifying as SAEs
Foreseeable AEs Unforeseeable AEs
May be reported if related to study treatment
 ► Bruising and discomfort at the venesection site
 ►Mild discomfort or minor bleeding from ATR site following injection
 ► Syncopal (fainting) episode associated with venesection or tendon 
injection
 ► Discomfort at ATR site during rehabilitation
 ► Technical complications of the lower leg casting and splinting
 ► Consequences of depending on walking aids
 ► Swelling or bruising of the lower leg and foot
 ► Deep vein thrombosis in a lower limb
 ► Rerupture of the treated Achilles tendon
Will be reported if related to treatment. 
For example:
 ► Serious infection of ATR injection site
 ► Skin breakdown or ulceration of treated lower 
leg other than ‘plaster sores’
 ► Severe pain requiring more than simple 
analgesia beyond 10 days after injection
AE, adverse event; ATR, Achilles tendon rupture; SAE, serious adverse event.
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expressed relative to the uninjured limb by computing 
a Limb Symmetry Index (LSI)=(/)×100. Participants 
are asked to stop by the assessor if any of the following 
is observed: volitional stopping due to fatigue, inability 
to keep pace with the metronome or maintain full knee 
extension of the standing leg or using more than fingertip 
support against the wall. The assessor uses verbal prompts 
if the above are observed and stops the test if the partici-
pant does not respond to two consecutive prompts. The 
test will be standardised through providing study-spe-
cific encoder and software, HRET training manual and 
one-to-one training to the blinded assessor in each centre. 
Since the encoder is a very sensitive device, it records even 
minimal movements that might not correspond to actual 
heel rises. To dismiss potential measurement errors, two 
researchers (at least one being a physiotherapist) blinded 
to treatment allocation will independently review the 
videos of all assessments and discount any invalid repe-
tition included in the HRET data. The primary and 
secondary outcome measures are presented in tables 2 
and 3.
In the two substudies, the outcome measures are 
defined according to the substudy analysis. The whole 
blood and PRP component substudy includes analysing 
full blood cell count (red cells, platelets and white cells) 
in all participants in both groups and analysing PRP 
components in the PRP group. PRP analysis includes: cell 
count, platelet activation status (basal resting status and 
after ex vivo activation) as a measure of quality and rele-
vant growth factor concentrations (PDGF, IGF-1, VEGF, 
fibroblast growth factor and TGF-β). All blood and PRP 
samples will be anonymised, placed in secure biological 
sample transport packaging and sent via tracked courier 
to a central laboratory (Institute of Inflammation and 
Ageing Laboratory at the University of Birmingham) for 
analysis.
In the immunohistochemistry substudy: 16 partici-
pants in one centre (Oxford) who have given informed 
consent to undergo the sample collection procedure will 
have tendon needle biopsy under ultrasound guidance at 
week 6 postintervention. The patients for this substudy 
will be the first eight consented in each arm at the Oxford 
site only, and the procedure is carried out by an expe-
rienced radiologist. Analysis includes tissue morphology, 
proliferation, apoptosis, vascularity, metabolic indicators 
and stem cell marker. The tissues will be stored for future 
analysis of relevant markers.
Data will be collected for all participants including those 
who do not receive the allocated intervention, unless they 
have withdrawn consent for follow-up. In order to obtain 
Table 5 Protocol substantial amendments
Amendment/
date Nature of amendment Rational
SA01
3 June 2015
 ► Record maximum height and number of heel rises 
in HRET
 ► Provide additional validation of the outcome 
measure
 ► Ask patient which intervention they think 
they received in 24-week postassessment 
questionnaire
 ► Assessment of success of blinding strategy
 ► Stipulate guidelines for rehabilitation  ► To accommodate local preferences while ensuring 
the integrity and success of the trial
 ► Added guidance if allocated intervention cannot 
be given
 ► Guidance was omitted in original protocol version
 ► Clarifications on the nature of the injury  ► Clarify injury type
SA02
8 March 2016
 ► Change inclusion criteria  ► Increase upper age limit with requirement of 
ambulatory status
 ► Increase recruitment period  ► 12 days postinjury instead of 7
 ► Extended scope physiotherapists can administer 
the intervention
 ► Pragmatic approach to accommodate for clinical 
practice
 ► Clarification of the ATR diagnosis  ► Clarification of the rupture location
 ► Clarification of anticoagulation  ► VTE prophylaxis requirement
 ► Randomisation and statistical alterations  ► Approval of randomisation and statistical plan
SA03
21 April 2017
 ► Extended 24 months follow-up  ► To study PRP on effect on the quality of the 
repaired Achilles tendon at 2 years postinjury
SA04
24 July 2017
 ► Extend recruitment by 2 months
 ► Increase sample size to 230
 ► DSMC blinded interim data analysis found HRET 
SD is 24 with larger variability in data. Sample size 
increased to guarantee 80% power
ATR, Achilles tendon rupture; DSMC, Data and Safety Monitoring Committee; HRET, heel-rise endurance test; PRP, platelet-rich plasma; VTE, 
venous thromboembolism.
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as complete set of outcome data as possible, several 
attempts will be made to contact participants by phone 
for follow-up at each time point, and if they are not avail-
able, the questionnaire will be sent by post.
study flow chart
The patient pathway and main study activities are shown 
in figure 2.
safety reporting
Since PRP is prepared from autologous blood, concerns 
of disease transmission and immunogenic reactions are 
eliminated. Although there have been no serious adverse 
events (SAEs) related to using PRP reported in the litera-
ture, we have systems in place to monitor all adverse events 
(AEs) and SAEs. AEs will be collected during the study 
treatment episode, and staff should report any events 
they become aware of up to and including the 24 months 
follow-up appointment. SAEs must be reported to the 
Chief Investigator within 24 hours of the local research 
team becoming aware of the event. Participants will be 
asked if they have experienced any complications during 
follow-up data collection (box, table 4). Non-blinding of 
participants is not anticipated unless there are compelling 
medical or safety reasons. If non-blinding is requested by 
a site PI, the CI and OCTRU will make a decision based 
on the reasons for the request. Deviations from protocol 
and other unexpected events will be recorded on an inci-
dent form and assessed by the study team for implications 
for the study.
data management
All data will be processed according to the Data Protec-
tion Act 1998, and all documents will be stored safely 
in confidential conditions. Data will be collected from 
participants and site personnel via paper case report 
forms which will be returned to the central trial office by 
post using a Freepost address (prepaid). Blood samples 
and needle biopsy samples sent for analysis will be anony-
mised at source and only identified using the unique 
study number and participant initials. The HRET test 
data are transferred via the linear encoder linked to a 
study-dedicated laptop then transferred from each site 
to Oxford by an encrypted Universal Serial Bus following 
each participant HRET, and the original data remain on 
the site laptop. Blood and PRP samples will be stored 
at the Centre for Translational Inflammation Research 
at the Birmingham University Research Laboratory 
and disposed of at the end of the study. Needle biopsy 
samples for those participants taking part in the substudy 
(n=16) will be stored in the Oxford Musculoskeletal 
Biobank. Data provided from the blood sample analysis 
or biopsy samples analysis will be entered into the study 
database in Oxford. All data transfers will use appro-
priate password protected and/or encrypted files. The 
study management team will conduct data entry into a 
study-dedicated database which is developed and main-
tained by the OCTRU.
sample size and statistical analysis
Two hundred and thirty patients (115 in each arm) will 
provide 80% power to detect a standardised difference 
of 0.4 in the LSI from the HRET measure of work at 24 
weeks postrandomisation and with 5% (two-sided) signifi-
cance allowing for 20% loss to follow-up. This is based on 
previous data18 where a clinically important difference of 
10% with SD of 20% was observed and blinded interim 
data analysis that showed SD of 24% for the overall 
sample. This sample size will also provide 90% power and 
5% (two-sided) significance to detect an effect size of 0.5 
in the ATRS, based on a difference of 11 and SD of 21.4 
(18). All comparative results will be presented as summary 
statistics with 95% CIs and reported in accordance with 
the non-pharmacological extension to the Consolidated 
Standards of Reporting Trial (CONSORT) statement.27 28
The primary statistical analysis will be carried out 
on the basis of intention-to-treat. The time window for 
collecting the HRET will be 2 weeks before the 24 weeks 
time point and up to 8 weeks after. The primary anal-
ysis to investigate the adjusted effect of PRP on ATR 
recovery will be multivariate linear regression, using 
the LSI as dependent variable, treatment as the main 
independent variable and the stratification factors plus 
other prognostic factors as additional independent 
variables. If the primary outcome data are normally 
distributed, the two groups (PRP×imitation injection) 
will also be compared using an unpaired Student’s t-test 
to explore the unadjusted effect of the intervention. If 
data on the primary outcome are not normally distrib-
uted, the first approach will be data transformation, 
but if normality cannot be achieved, a non-parametric 
statistical test without adjustment will be used.
The PROMs (secondary outcomes) will be analysed in 
a linear mixed-effects model with longitudinal framework 
to allow data collected at all time points to be taken into 
account. This is a robust procedure that deals with some 
missing values; however, missing data imputation will be 
carried out if necessary. Similarly to the primary outcome, 
unadjusted analysis and data transformation (if neces-
sary) will also be performed for all continuous secondary 
outcomes. Descriptive statistics (such as means and SD for 
continuous variables and frequencies and proportions for 
categorical or binary variables) will be used to describe 
the baseline characteristics of the participants in the two 
study groups; however, no formal statistical tests will be 
used to compare the groups.
For the two substudies, statistical analyses will be 
primarily descriptive, and the relationship between 
various biomarkers and clinical outcomes will be 
explored.
A separate statistical analysis plan (SAP) will contain 
full details of all statistical analyses and will be prepared 
early in the trial, agreed with the Data and Safety Moni-
toring Committee (DSMC) and finalised prior to the 
primary analysis database lock and before non-blinding 
of the data. Any changes at this time will be incorporated 
into the final SAP and signed off as per current OCTRU 
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standard operating procedures (SOPs). Any changes/
deviations from the original SAP will be described and 
justified in the protocol and/or in the final report, as 
appropriate. Comparative outcome interim analyses are 
not planned unless requested by the DSMC.
Ethics and dissemination
This trial will be conducted in accordance with the 
ethical principles that have their origin in the Declara-
tion of Helsinki and that are consistent with GCP and 
the applicable requirements as stated in the Research 
Governance Framework for Health and Social Care 
(second edition 2005). The study may be monitored 
or audited in accordance with the current approved 
protocol, GCP, relevant regulations and SOPs.29. An 
independent DSMC is established to safeguard the 
interests of trial participants, potential participants 
and future patients, to assess the safety and efficacy of 
the interventions during the trial and to monitor the 
overall conduct of the trial, protecting its validity and 
credibility. DSMC will adopt the DAMOCLES charter30 
and meet at least annually, with an option to increase if 
specific concerns arise. Local NHS trust approval and 
contract with the sponsor is required before recruit-
ment initiation at each site. The study may be audited 
by the sponsor or the clinical trials unit. The study office 
team will conduct monitoring visits to sites as defined in 
the Risk Assessment and Monitoring Plan.
The trial will be reported in accordance with the 
CONSORT statement31 and its extensions relating to 
non-pharmacological studies27 32 and TIDieR (template 
for intervention description and replication) guide-
lines for intervention description and replication.33 
A summary of the trial outcome will be disseminated 
to trial participants on relevant websites and by email, 
where an email address is provided. In addition to the 
NIHR monograph report, the results will be published in 
peer-reviewed medical literature and may be presented 
at relevant national and international conferences.
Amendments to the protocol
Amendments will be handled through Health Research 
Authority (HRA) procedures. Two substantial amend-
ments have been implemented since the study began 
(table 5). The first amendment was submitted prior to 
commencement of the trial to add additional informa-
tion, rehabilitation guidance and blinding assessment. 
The second amendment was performed after 40 patients 
were recruited to change recruitment criteria, clarify 
diagnosis, clarify anticoagulation and update the rando-
misation mechanism and statistical plan. The change to 
randomisation was required due to imbalance in partic-
ipants’ age group stratum following a systems issue. The 
underlying systems issue was fixed, and a change to the 
randomisation strategy was implemented to avoid this 
imbalance being preserved throughout the study. The 
randomisations allocated prior to the change were not 
altered. This approach was reviewed and approved by 
the sponsor, DSMC, Trial Steering Committee (TSC) 
and the Ethics Committee.
dIsCussIon
This multicentre trial opened to recruitment in July 2015 
and will reach recruitment targets in September 2017. 
The trial is due to report results in July 2018.
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